LOGIN  |  REGISTER

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

October 30, 2023 | Last Trade: US$0.86 0.0062 -0.71

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

Conference Call Information

When: Monday, November 6, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI0eececfba52f4f83a7438c9f002fabc4

Webcast: https://edge.media-server.com/mmc/p/z2fatkzx

A press release containing the third quarter financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call. Please also review our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, which will be available at https://investors.coherus.com and available via EDGAR on the SEC’s website at www.sec.gov on November 6, 2023 for more information about our third quarter financial results.

A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.

Coherus Contact Information:
Jodi Sievers
VP, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page